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Dendritic cells are equipped with lectin receptors to sense the extracellular environment and modulate cellular
responses. Human plasmacytoid dendritic cells (pDCs) uniquely express blood dendritic cell antigen 2 (BDCA2) protein,
a C-type lectin lacking an identifiable signaling motif. We demonstrate here that BDCA2 forms a complex with the
transmembrane adapter FceRIc. Through pathway analysis, we identified a comprehensive signaling machinery in
human pDCs, similar to that which operates downstream of the B cell receptor (BCR), which is distinct from the system
involved in T cell receptor (TCR) signaling. BDCA2 crosslinking resulted in the activation of the BCR-like cascade, which
potently suppressed the ability of pDCs to produce type I interferon and other cytokines in response to Toll-like
receptor ligands. Therefore, by associating with FceRIc, BDCA2 activates a novel BCR-like signaling pathway to regulate
the immune functions of pDCs.
Citation: Cao W, Zhang L, Rosen DB, Bover L, Watanabe G, et al. (2007) BDCA2/FceRIc complex signals through a novel BCR-like pathway in human plasmacytoid dendritic
cells. PLoS Biol 5(10): e248. doi:10.1371/journal.pbio.0050248
Introduction
Dendritic cells (DCs) are specialized sentinels in the
immune system that detect invading pathogens and patho-
logical damages of the host. Upon activation, DCs instruct
appropriate and effective immune responses [1–3]. Their
extraordinary ability to capture antigens (self or foreign) is
largely mediated by the collective expression of C-type lectin
receptors (CLRs) on the cell surface [4,5]. In mouse spleen, DC
subsets display a discrete expression proﬁle of C-type
lectins—CD8
þ DCs express DEC-205 (CD205), whereas CD8
 
DCs express dendritic cell immunoreceptor 2 (DCIR2),
dendritic cell immunoactivating receptor (DCAR), Dectin-1,
Dectin-2, DCIR3, and DC-SIGN [6]. This expression proﬁle, in
conjunction with the polarized expression of antigen process-
ing and presentation machinery, contributes to the intrinsic
functional difference between the DC subsets in regulating
immunity [6]. In humans, C-type lectin ICAM3-grabbing
nonintegrin (DC-SIGN, CD209) is expressed by mucosal DCs
and langerin (CD207) is expressed by Langerhans cells [3,4].
Besides tissue DCs, macrophage, myeloid DCs (mDCs) and
monocytes express a number of CLRs, such as Dectin-1,
macrophage mannose receptor (MMR), and DCIR [3,4].
Plasmacytoid DCs (pDCs), also referred to as natural type I
interferon (IFN)-producing cells (IPCs), are a distinct DC
population with an extraordinary ability to rapidly produce
massive amounts of type I IFN in response to viral infections
[7,8]. Blood dendritic cell antigen 2 (BDCA2), a C-type lectin
uniquely expressed on resting human pDCs, has been used to
unequivocally identify pDCs in human peripheral blood and
tissues [9]. It has an intracellular N terminus and only one
extracellular carbohydrate recognition domain, which be-
longs to the type II C-type lectin group [5,10,11]. Similar to
CLRs on other DC subsets, BDCA2 has been suggested to be
capable of functioning as an antigen-uptake receptor,
because monoclonal antibodies (mAbs) bound to BDCA2 on
the surface of pDCs are efﬁciently internalized, and mAb-
derived peptide bound to MHC class II can be presented to T
cells [10].
Resting pDCs uniquely express high amounts of Toll-like
receptor 9 (TLR9) and TLR7 [12–14], which recognize
microbial DNA or RNA ligands in the endo-lysosomal
compartment, respectively. After activation of TLR7 or
TLR9, a multi-component ‘‘cytoplasmic transductional–tran-
scriptional complex’’ is formed to initiate cellular activations
[15–17]. Type I IFN production by pDCs has been shown to be
independent of RNA helicases retinoic acid–inducible gene I
(RIG-I), melanoma differentiation-associated gene 5 (MDA5)
and their adaptor IFN-ß promoter stimulator-1 (IPS-1)
[15,18–20], which are essential for IFN response to viruses
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PLoS BIOLOGYby other immune or nonhematopoietic cells. Therefore, pDCs
carry out their unique innate immune functions through the
TLR-mediated pathway. After exposure to viruses, pDCs
differentiate into efﬁcient antigen-presenting DCs and thus
act as a critical mediator linking innate and adaptive immune
responses against viral infections [7,8]. However, aberrant
pDC activation in the absence of infection has been
associated with autoimmune diseases. Patients with active
systemic lupus erythematosus (SLE) have high amounts of
type I IFN in their sera, which is likely due to the activation of
pDCs by autoantibodies complexed with self nuclear antigens
[21–24]. Because both TLR7 and TLR9 are located intra-
cellularly, how pDCs sense the extracellular microenviron-
ment and, in turn, modulate these TLR-mediated responses
remains an important question.
BDCA2 was the ﬁrst receptor described that negatively
regulates the IFN response of pDCs, which is induced by CpG
oligonucleotide, inﬂuenza virus, or by autoantibodies com-
plexed with DNA [25,26]. However, it is not clear how BDCA2
modulates the TLR signaling, because its cytoplasmic domain
does not contain any known signaling motifs, even though
BDCA2 ligation by mAbs causes protein tyrosine phosphor-
ylation and calcium inﬂux [25]. A recent analysis of the closely
related dendritic cell immunoreceptor family lectins, which
include DCIR, DCAR, Dectin-2, and BDCA2, suggests a
potential shared signaling mechanism as a result of the similar
arrangement of their transmembrane domains [11,27,28].
Both DCAR and Dectin-2 have been shown to associate with
FceRIc to transduce cellular activation signals [29,30].
Here we report that BDCA2 signals in pDCs by associating
with the transmembrane adapter FceRIc and initiates an
immunoreceptor-based tyrosine activation motif (ITAM)–
dependent signaling cascade. We also provide evidence that
human pDCs express a series of signaling molecules known to
be speciﬁcally involved in BCR activation. We demonstrate
that the BDCA2 and FceRIc complex activates a prominent
BCR-like signaling pathway in human pDCs to modulate the
TLR-mediated responses.
Results
BDCA2 Associates with and Signals through FceRIc
To determine the expression proﬁle of BDCA2 in human
leukocytes, we searched our established gene expression
database, which includes the major immune cell types in
peripheral blood. Strikingly, BDCA2 transcripts were ex-
pressed abundantly and exclusively by human pDCs (Figure
1A), consistent with its speciﬁc surface expression on pDCs
within total peripheral blood mononuclear cell (PBMC) [9].
By contrast, immature peripheral blood CD11c
þ mDC,
monocyte, and monocyte-derived DC (mono-DC) expressed
transcripts of other C-type lectins, such as DC-SIGN, Dectin-
1, DCIR, and MMR, which were absent in pDCs (Figure 1A).
pDCs express two transmembrane adapter proteins bear-
ing ITAMs, i.e., FceRIc and DAP12, as well as DAP10, which
signals via a YINM motif to activate PI3K [31]. To test whether
BDCA2 interacts with any of these adapters, the individual
adapters were ﬁrst stably transduced into Jurkat cells, a
human T cell line. When BDCA2 was transfected into Jurkat
cells containing FceRIc, the expression of BDCA2 on the cell
surface was greatly enhanced, indicating a potential inter-
action between BDCA2 and FceRIc (Figure 1B). In contrast,
the presence of DAP12 and DAP10 only marginally affected
BDCA2 expression, whereas both DAP12 and DAP10 in-
creased the surface expression of mouse NKG2D, used as a
positive control [31]. The enhanced BDCA2 surface expres-
sion in the presence of FceRIc was also observed in several T
and B cell lines (Figure S1). To demonstrate directly the
physical association between BDCA2 and FceRIc, we per-
formed co-immunoprecipitation experiments and showed
that FceRIc existed in a complex that could be precipitated by
antibody to BDCA2, but not by an isotype-matched control
antibody from transfected Jurkat cells (Figure 1C) and,
furthermore, from freshly isolated human pDCs (Figure 1D).
These data suggest that BDCA2 and FceRIc form a receptor
complex with signaling potential.
Previously, BDCA2-transfected Jurkat cells were shown to
be unable to initiate protein tyrosine phosphorylation after
BDCA2 crosslinking, an observation suggesting the potential
involvement of a signaling adapter [25]. When BDCA2 was
crosslinked on the Jurkat cells that were cotransfected with
different adapters, Jurkat cells expressing FceRIc, but not
DAP12 or DAP10, prominently phosphorylated a spectrum of
proteins (Figure 2A). We constructed a mutant FceRIc in
which the tyrosine (Y) residue within the intracellular ITAM
was replaced with phenylalanine (F), rendering it unable to
recruit downstream molecules. This mutant FceRIc sup-
ported the elevated levels of surface expression of BDCA2
(Figure 1B) but was unable to mediate the protein tyrosine
phosphorylation after BDCA2 crosslinking (Figure 2B),
indicating an essential role of the ITAM in FceRIc for the
signaling by the BDCA2/FceRIc complex.
Furthermore, when a human BDCA2/FceRIc complex was
introduced into a mouse T cell hybridoma line that contained
an intracellular nuclear factor of activated T cells–green
ﬂuorescent protein (NFAT-GFP) reporter construct [31,32],
crosslinking BDCA2 by mAb resulted in GFP expression
(Figure 2C), indicating that the BDCA2/FceRIc receptor
complex was able to activate NFAT, similar to the effect of
TCR-induced activation. In the absence of FceRIc, cross-
linking BDCA2 did not induce GFP expression (Figure 2C).
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Author Summary
Dendritic cells (DCs) are specialized sentinels in the immune system
that detect invading pathogens and, upon activation, initiate
immune responses. DCs express C-type lectin receptors on their
surface, which facilitate antigen capture. A distinct population of
DCs, called plasmacytoid DCs (pDCs), display an extraordinary ability
to rapidly make huge amounts of antiviral interferon (IFN) against
viral infections. Human pDCs uniquely express a C-type lectin
named BDCA2 that potently regulates pDCs function, yet the
mechanism of how BDCA2 transduces signals is unknown. We show
here that BDCA2 forms a complex with the transmembrane adapter
FceRIc. Using signaling pathway analysis, we discovered a compre-
hensive signaling machinery in human pDCs, similar to that which
operates downstream of B cell receptors (BCRs), but distinct from
the pathway involved in T cell receptor signaling. By associating
with FceRIc, BDCA2 activates a novel BCR-like signaling pathway to
regulate the immune functions of pDCs. Since several pDC receptors
use this pathway to modulate IFN and cytokine responses, these
findings will guide more studies on how pDCs are regulated. Such
mechanisms may lead to potential therapeutic interventions in
autoimmune diseases involving hyperactivated pDCs, such as
systemic lupus erythematosus and psoriasis.Finally, calcium inﬂux, one of the important cellular
activation events that occurs downstream of ITAM signaling,
was effectively triggered by BDCA2 crosslinking in Jurkat
cells transfected with both BDCA2 and FceRIc, but not in
cells transfected with BDCA2 alone (Figure 2D), further
conﬁrming the requirement of FceRIc for BDCA2 to signal.
Human pDCs Express Signaling Molecules Involved in BCR
Activation
To further delineate the intracellular signaling events
following BDCA2 and FceRIc activation, we examined the
expression by pDCs of components known to be involved in
ITAM-mediated signaling. In lymphocytes, several well-
established signaling pathways exist downstream of the B cell
and T cell antigen receptors, linked through ITAM-bearing
subunits of these receptor complexes. We analyzed the
expression of molecules involved in BCR and TCR activation
in pDCs in comparison with peripheral B cells, T cells, natural
killer (NK) cells, mDCs, and monocytes.
After receptor activation, two core tyrosine residues within
t h eI T A M ( s )a r ep h o s p h o r y l a t e db yS r cf a m i l yp r o t e i n
tyrosine kinases (PTKs). The phosphorylated tyrosines within
the ITAMs associate with the src homology 2(SH2) domains of
Syk-family PTKs, which in turn phosphorylate cell-type–
speciﬁc intracellular adapters to initiate a multitude of
signaling events. Each type of lymphocyte expresses and uses
a distinct set of proteins to carry out the receptor-proximal
signal transduction [33,34]. B cells express B lymphoid
tyrosine kinase (BLK), Lyn kinase, spleen tyrosine kinase
(Syk), and two adapter molecules, BLNK and BCAP, whereas
T cells preferentially use two other Src-family PTKs, Fyn and
Lck, and CD3n-associated protein kinase (ZAP-70) from the
Syk-family of PTKs, as well as alternative adapters, i.e., SLP-76
and linker for activation of T cells (LAT) (Figure 3A).
Strikingly, pDCs express many members of the BCR signaling
cascade, but not those involved in TCR activation (Figure 3A).
Of note, the levels of the B cell–speciﬁc adapter B cell linker
(BLNK, also known as SLP-65 or BASH) was transcribed at
higher levels in pDC than in B cells (514 relative units versus
133 relative units, respectively). Another B cell adapter,
BCAP, which mediates phosphoinositide-3-kinase (PI3K)
signaling [35], was also abundantly expressed by pDCs (Figure
3A). pDCs expressed lower levels of BLK compared to B cells.
Interestingly, NK cells, in addition to expressing several
members of the TCR signaling pathway, were found also to
express several molecules involved in BCR signaling, e.g., Lyn,
Syk and BCAP. mDC and monocyte similarly express Lyn,
Syk, BCAP, and Fyn as well as the T cell adaptor SLP76.
H o w e v e ru n l i k ep D C sa n dBc e l l s ,t h e yb o t hl a c kt h e
expression of BLNK and BLK (Figure 3A). Within all the
peripheral cell leukocytes we examined, BLNK transcripts
were only transcribed by pDCs and B cells (unpublished data).
We next analyzed the expression of the signaling compo-
nents operating downstream of the molecules described
above. pDCs and B cells selectively transcribed PLCc2,
Vav2, and Vav3, which are absent in T cells (Figure S2). On
the other hand, high levels of PKCh are abundantly expressed
by T and NK cells, but not by pDCs or B cells (Figure S5). In
contrast, the expression of other downstream signaling
molecules, such as PI3K, Nck, MAP kinases, and NFAT, failed
to show a distinct cell type–speciﬁc pattern (Figure S2).
We conﬁrmed the transcription and protein expression of
the BCR proximal signaling molecules in pDCs from several
healthy donors by RT-PCR and Western blot analysis (Figure
3B and 3C). Taken together, our analysis revealed the
existence of a potential ITAM-mediated signaling cascade in
human pDCs similar to that of B cells, but distinct from that
in T cells, NK cells, monocytes, or mDCs (Figure 4).
Figure 1. BDCA2 Associates with FceRIc To Form a pDC-Specific Receptor Complex
(A) The expression profile of BDCA2 transcripts in peripheral blood leukocytes by microarray gene expression analysis is shown. In comparison, the
relative expression levels of DC-SIGN, Dectin-1, DCIR, and MMR are also shown. A value of ,1 (arbitrary units) indicates the absence of gene expression.
(B) Surface expression of BDCA2 after transduction of BDCA2 into Jurkat cells previously transfected with control, FceRIc, DAP12, DAP10, or a Y-F ITAM
mutant FceRIc. The surface staining by isotype-matched control mAb is shown as a shaded area.
(C) Co-immunoprecipitation of BDCA2 and FceRIc from BDCA2 and FceRIc doubly transfected Jurkat cells after cell surface biotinylation. Western blot
analysis was performed with anti-FceRIc Ab or with HRP-conjugated NeutrAvidin.
(D) Co-immunoprecipitation of BDCA2 and FceRIc from freshly isolated pDCs. Western blot analysis was performed with anti-FceRIc Ab.
doi:10.1371/journal.pbio.0050248.g001
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BDCA2/FceRIc Activates BCR-Cascade in Human pDCsBDCA2/FceRIc Complex Transduces Signals via a BCR-Like
Signaling Cascade
To investigate whether the BDCA2/FceRIc receptor com-
plex could signal through the BCR signaling cascade, Namalwa
cells, a human Burkitt lymphoma cell line, was transfected
with BDCA2 and FceRIc. Similar to BCR activation, cross-
linking of the BDCA2/FceRIc complex on Namalwa cells
resulted in rapid phosphorylation of residue Y525 of Syk and
residue Y416 of Src-family PTKs (Figure 5). After BCR
activation, ﬁve tyrosine residues on BLNK are phosphory-
lated, enabling its function as a scaffold to integrate and
propagate signals to downstream proteins [36]. BDCA2
ligation resulted in phosphorylation of residue Y84 of BLNK
(Figure 4). Additional downstream molecules, such as Vav1
and PLCc2, were phosphorylated by BDCA2 crosslinking,
similar to BCR activation (Figure 5). MAP kinases Erk1/2,
which are also activated after BCR engagement through the
Ras-Raf pathway, were rapidly phosphorylated after BDCA2
stimulation (Figure 5). Furthermore, we observed a robust
Ca
þþ inﬂux in Namalwa cells after BDCA2 crosslinking, which
is dependent on FceRIc (unpublished data).
To study the signaling of the BDCA2/FceRIc complex in
primary human pDCs, we crosslinked BDCA2 by mAbs on
freshly isolated pDCs and conﬁrmed that it potently induces a
transient intracellular calcium ﬂux (Figure 6A). This activity
was inhibited by PP2, a compound that inhibits Src family
PTKs, but was not affected by an inactive control compound,
PP3. In addition, Syk inhibitor completely abolished the
intracellular calcium ﬂux in BDCA2-crosslinked pDCs (Figure
6A). These results suggest the functional involvement of both
Syk and Src-family PTKs during BDCA2 signaling. When the
phosphorylation status of key signaling molecules in pDCs
was analyzed, BDCA2 crosslinking resulted in rapid phos-
phorylation of both Src family PTKs and Syk (Figure 6B),
indicating the onset of ITAM-induced signaling in pDCs.
Different from the results with the Namalwa cell line, BDCA2
crosslinking did not enhance the pre-existing phosphoryla-
tion of BLNK in pDCs (Figure 6B, lane 5). High levels of
phosphorylation of Y84 in the BLNK protein have been
observed in freshly isolated, resting pDCs from several
healthy donors, but not in freshly isolated human B cells
(unpublished data). Moreover, downstream molecules, in-
cluding Vav1, PLCc2, and Erk1/2, were phosphorylated by
BDCA2 crosslinking on pDCs (Figure 6B). In contrast,
crosslinking with neither the isotype-matched control anti-
body nor the mAb against BDCA-4, another surface molecule
expressed on pDCs, phosphorylated these proteins under the
same conditions (Figure 6B). It should be noted that BDCA-4
beads were used to isolate pDCs, therefore BDCA-4 may no
longer available for efﬁcient crosslinking. The Src PTK
inhibitor PP2 or Syk inhibitor, but not PP3, greatly
diminished BDCA2-induced phosphorylation of both Src
family PTKs and Syk and blocked the phosphorylation of
Vav1 and PLCc2( F i g u r eS 3 ) .T h u s ,t h eB D C A 2 / F c eRIc
Figure 2. Crosslinking the BDCA2/FceRIc Complex Transduces Activation Signals
(A) Total protein phosphorylation in Jurkat cells transfected with BDCA2 in the absence or presence of adapter proteins by anti-BDCA2 mAb or control
IgG1 crosslinking. Western blot analysis was performed with anti-phosphotyrosine mAb PY20.
(B) Total protein phosphorylation induced by anti-BDCA2 mAb crosslinking in Jurkat cells transfected with BDCA2 and wild-type (WT) or mutant (Y-to-F)
FceRIc.
(C) Transfected mouse 2B4 T hybridoma cells with an NFAT-GFP reporter (transgenes are labeled on the top) were crosslinked with control mouse IgG1
or anti-BDCA2 mAb. Cells were analyzed for GFP expression by flow cytometry. Cells cultured in medium alone or with ionomycin (positive control)
were also analyzed.
(D) The kinetics of intracellular calcium flux in transfected Jurkat cells (transgenes are labeled on top) when crosslinked (marked by arrow) by control
(IgG1) or anti-BDCA2 mAb.
doi:10.1371/journal.pbio.0050248.g002
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BDCA2/FceRIc Activates BCR-Cascade in Human pDCscomplex signals through a BCR-like signaling cascade in
primary human pDCs.
BDCA2/FceRIc Complex Signaling Inhibits TLR-Mediated
Type I IFN Production
Although BCR signaling synergizes with TLR triggering for
optimal B lymphocyte activation [37], the impact of this
pathway on TLR-mediated type I IFN responses needs to be
deﬁned. To accomplish this, we stably transfected human
Burkitt lymphoma Namalwa cells with IRF7, BDCA2 and
FceRIc. These cells with endogenous TLR9 expression [38]
produced IFNa in response to stimulation with CpG
oligonucleotide (ODN) (Figure 7A). Crosslinking of BDCA2/
FceRIc or BCR together with CpG activation in these
Namalwa cells resulted in enhanced interleukin 10 (IL-10)
production, as expected, but decreased IFNa secretion
(Figure 7A), indicating a selective suppressive effect by BCR
or BDCA2 activation on TLR-induced IFNa production.
To investigate the function of the BCR-like signaling
cascade in pDCs, we analyzed, in detail, the impact of BDCA2
crosslinking on the innate immune responses of human
primary pDCs. Puriﬁed pDCs were stimulated with CpG ODN
2216 or R848, ligands of TLR9 and TLR7 or TLR8,
respectively, in the presence of anti-BDCA2 mAb or control
mAbs. BDCA2 ligation potently inhibited IFNa production
and invariably reduced the production of tumor necrosis
factor a (TNFa) and IL-6 induced by stimulation with these
TLR ligands (Figure 7B). pDCs secreted lower levels of IFNa
after BDCA2 ligation, but normal amounts of chemokines
CXCL10/IP-10, CCL3/MIP-1a and CCL4/MIP-1b in response
to CpG (Figure S4).
To evaluate the kinetics of BDCA2-mediated suppression
of IFN production, pDCs were ﬁrst stimulated with CpG and
control or anti-BDCA2 mAbs were added to the culture at
different times afterward. Strikingly, up to 4 h after pDCs
were exposed to CpG ODN, crosslinking BDCA2 by mAb
effectively inhibited IFNa and cytokine production by pDCs
(Figure 7C). This result demonstrates the potency of BDCA2
Figure 3. Human pDCs Express a BCR-Like Signaling Cascade
(A) Expression of genes encoding molecules involved in BCR (top panel) and TCR (bottom panel) signaling in six peripheral leukocyte cell types from
microarray gene expression analysis.
(B) The relative gene expression of signaling molecules in different cell types from three healthy donors determined by quantitative RT-PCR analysis. The
expression was normalized with the level of the transcript in total PBMC. The median expression is marked by a horizontal bar.
(C) The expression of signaling proteins in different cell types was determined by Western blot analysis. The results from one representative donor out
of three healthy donors analyzed are shown.
doi:10.1371/journal.pbio.0050248.g003
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pDCs. Independently, pDCs from multiple donors were
stimulated simultaneously with both CpG and anti-BDCA2
or control mAbs and at different lapsed times, the amounts of
IFNa in the supernatant were measured (Figure S5). At 4 h
after CpG treatment, pDCs treated with anti-BDCA2 mAbs
reduced the production of IFNa by 96%. By 8 h post CpG
treatment, BDCA2-ligated pDCs produced an average of
25.6% of IFNa compared to the amount made by control
IgG1-incubated pDCs (Figure S5). Therefore, BDCA2 cross-
linking likely blocked the initial induction of IFNa secretion.
To further determine the stage of IFN suppression, we
measured the amount of type I IFN transcripts from CpG-
activated pDCs that were crosslinked with anti-BDCA2 or
control mAbs. BDCA2 crosslinking uniformly reduced the
transcription of all the subtypes of type I IFN analyzed, i.e.,
IFNa, IFNb, IFNc, and IFNx (Figure 7D). Therefore, BDCA2
ligation blocks the transcriptional of type I IFN by pDCs in
response to TLR activation.
Discussion
To date, BDCA2 is the only C-type lectin that is found
expressed exclusively on human pDCs, and it serves as a
deﬁning marker for pDCs. In addition, BDCA2 represents
one of the most potent receptors that modulates the ability of
pDCs to elicit type I IFN responses. Here we provide
experimental evidence to reveal the signaling mechanism
used by BDCA2 in human pDCs. On the cell surface, BDCA2
associates with FceRIc to form a signaling receptor complex,
which, upon ligation, activates a novel BCR-like intracellular
signaling cascade, interfering with TLR activation.
Figure 4. Diagram of ITAM-Mediated Signaling Pathways in Human Leukocytes
The schematic cascades that are involved in receptor proximal signaling (solid arrows) and those leading to NF-jB activation (dotted lines) are shown.
doi:10.1371/journal.pbio.0050248.g004
Figure 5. BDCA2/FceRIc Complex Signals through the BCR Signaling Cascade in Transfected B Cells
Shown are the kinetics of tyrosine phosphorylation of BCR intracellular signaling components in transduced Namalwa cells when crosslinked by control
IgG1 or anti-BDCA2 mAb in comparison with BCR activation by anti-human Ig Ab.
doi:10.1371/journal.pbio.0050248.g005
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BDCA2/FceRIc Activates BCR-Cascade in Human pDCsITAM-based signaling is the primary pathway of activation
used by classical immunoreceptors, such as the antigen
receptors on B and T lymphocytes, NK cell receptors, and
the Fc receptors on myeloid cells [39–41]. ITAM-mediated
signaling is also used by additional receptors, such as cell
adhesion molecules, chemokine receptors, plexins, and lectin
receptors [42]. pDC and mDCs represent two major subsets of
professional antigen-presenting cells in human peripheral
blood and tissues, which use different sets of pattern
recognition receptors, such as TLRs, CLRs, and Nod-like
receptors, for sensing and responding to microbial infections
[43–50]. Our present study suggests that mDCs and pDCs not
only express different repertories of lectin receptors, but also
suggests that the signal pathways used by CLRs bearing ITAM
elements on mDC and pDCs are intrinsically different.
Ligation of either the BDCA2/FceRIc complex or certain
myeloid cell lectins, such as Dectin-1 and DC-SIGN [51,52],
phosphorylates Syk, which is involved in BCR membrane-
proximal signaling. However, downstream of Syk, pDCs use
the intracellular adaptor molecule BLNK, whereas mDCs use
SLP76 for ampliﬁcation of signaling (Figure 7). In addition,
recent studies showed that CARD9, a signaling adaptor
molecule, plays a critical role in the signal transduction of
Dectin-1 and ITAM-associated receptors in myeloid cells
[53,54]. Our analysis suggests that similar to lymphocytes,
pDCs do not express CARD9, but likely use CARMA1 (also
named CARD11) to activate nuclear factor jB (NF-jB) [55–
57] (Figure S6 and Figure 7).
Previous studies have shown remarkable similarities be-
tween B lineage cells and pDCs, including their plasma cell
morphology and shared expression of several classes of genes.
For example, they express a similar sets of TLRs (TLR7 and
TLR9) [12,14,58], possess germ-line immunoglobulin (Ig)
transcripts and Ig recombinase [59–61], have B cell–related
transcription factor Spi-B [59,62], and use the same CIITA
promoter for the controlling of MHC Class II expression [63].
The present demonstration that the pDC receptor BDCA2/
FceRIc and BCR share the same membrane-proximal signal-
ing cascade and pathway leading to NF-jB activation
provides further support for the intriguing relationship
between pDCs and B lymphocytes.
A central mediator during B cell activation, BLNK, is
phosphorylated by BCR activation on ﬁve tyrosine residues
(Y72, Y84, Y96, Y178, and Y189) that serve as docking sites for
recruiting downstream molecules [34,36]. Interestingly, in
resting primary pDCs, we observed high levels of, if not
saturating, phosphorylation of Y84 in BLNK, which is
involved in PLCc2 activation [36]. Further examination of
Figure 6. BDCA2/FceRIc Complex Signals through a BCR-Like Signaling Cascade in Primary pDCs
(A) The kinetics of intracellular calcium flux in freshly isolated pDCs when crosslinked (marked by arrow) by control IgG1 or anti-BDCA2 Ab. As indicated,
cells were pre-incubated with PP2, PP3, or Syk inhibitor prior to crosslinking.
(B) The kinetics of tyrosine phosphorylation on BCR intracellular signaling components in freshly isolated pDCs when crosslinked by control IgG1, anti-
BDCA2 mAb, or anti-BDCA-4 mAb.
doi:10.1371/journal.pbio.0050248.g006
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shed light on the dynamic involvement of this key molecule in
nucleating signaling components during BDCA2 activation.
A recent study reported that BDCA2 may serve as an
alternative receptor, in addition to CD4, CXCR4, and CCR5
on human pDCs, for HIV via binding to gp120 [64].
Therefore, it is plausible that HIV uptake by BDCA2
negatively affects the ability of pDCs to mount type I IFN
responses. Similarly, Mycobacterium tuberculosis targets DC-
speciﬁc C-type lectin DC-SIGN to infect DCs and to directly
down-regulate DC-mediated immune responses [65]. More-
over, measles virus (MV) interacts with CD46, its cellular
receptor on human monocytes, to speciﬁcally down-regulate
IL-12 production, a mechanism causing MV-induced immu-
nosuppression [66]. Therefore, BDCA2 may represent anoth-
er example of antigen uptake receptors targeted by microbial
ligands to negatively regulate cellular immunity.
Paradoxically, activation by antigens through the BCR
triggers B cell proliferation, differentiation, and Ig and
cytokine production, whereas crosslinking of BDCA2, which
activates a similar BCR-like signaling pathway, fails to
stimulate pDCs to proliferate or produce cytokines [10] (W.
Cao, unpublished data), but rather inhibits the TLR-mediated
responses. As multiple receptors on pDCs apparently use
ITAM-based mechanisms to modulate type I IFN and cytokine
responses during TLR activation [17,31,67–70], our ﬁndings
will facilitate further investigations to determine how TLR
activation is regulated in pDCs. Such mechanisms may
provide opportunities for therapeutic interventions in auto-
immune diseases, such as SLE [24], Sjo ¨gren syndrome [71,72],
polymyositis [73,74], and psoriasis [75,76], where the causative
mechanisms might involve hyper-activation of pDCs.
Materials and Methods
Media, cell lines, and reagents. RPMI-1640 medium supplemented
with 2 mM L-glutamine, 100 U/ml penicillin, 100 ng/ml streptomycin
(Invitrogen; http://www.invitrogen.com), and heat-inactivated 10%
FBS (Atlanta Biologicals; http://www.atlantabio.com) were used for the
cell culture. The human acute T cell leukemia cell line Jurkat and the
Burkitt lymphoma cell line Namalwa were purchased from the
American Type Culture Collection (ATCC). The mouse 2B4 T
hybridoma cell line was generously provided by H. Arase, Osaka
University, Japan. CpG ODN 2216 (GGGGGACGATCGTCGG-GGGG
and CpG 2006 (TCGTCGTTTTGTCGT-TTTGTCGTT) (Qiagen;
http://www.qiagen.com) and R848 (InVivogen; http://www.invivogen.
com) were used for pDC stimulation.
Immune cell isolation and establishment of gene expression
database. The institutional review board for human research at the
M.D. Anderson Cancer Center approved this study. Our gene
expression database containing multiple types of immune cells
isolated from human peripheral blood was established as described
[31]. For this study, four peripheral leukocyte cell types were isolated
simultaneously from buffy coats of individual healthy donors. Brieﬂy,
pDCs were positively selected from PBMC with anti-BDCA-4-coated
Figure 7. Ligation of the BDCA2/FceRIc Complex Inhibits TLR-Induced Type I IFN Production
(A) Transfected Namalwa cells were stimulated with CpG ODN and ligated with anti-BDCA2, anti-BCR, or control mAbs. Shown are the amounts of IFNa
and IL-10 secreted by the cells stimulated CpG in a triplicate assay.
(B) Purified pDCs were stimulated by CpG (top panel) or R848 (bottom panel) following anti-BDCA2 or control mAb crosslinking. The amounts of the
secreted IFNa, TNFa, and IL-6 in a triplicate assay from a representative donor (n   3) are shown.
(C) Purified pDCs stimulated by CpG first and then treated with anti-BDCA2 or control mAbs at different time intervals. The amounts of the secreted
IFNa, TNFa, and IL-6 from a representative donor (n   3) are shown.
(D) The amounts of type I IFN transcripts were determined by quantitative RT-PCR analysis. The expression is shown as the relative level of transcription
compared with unstimulated PBMC.
doi:10.1371/journal.pbio.0050248.g007
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 CD4
þCD8
 CD11c
 
CD14
 CD16
 CD19
 CD56
 . The remaining PBMCs were stained and
individual cell types were sorted accordingly: B cells (CD4
 CD8
 
CD11c
 CD14
 CD16
 CD19
þCD56
 CD235a
 BDCA2
 ), CD4
þ Tc e l l s
(CD4
þCD8
 CD11c
 CD14
 CD16
 CD19
 CD56
 CD235a
 BDCA2
 ), and
NK cells (CD3
 CD4
 CD8
 CD14
 CD19
 CD56
þCD235a
 BDCA2
 ).
Quantitative real-time PCR. Total RNA extraction and quantita-
tive real-time (RT)-PCR were performed as described [31]. Oligonu-
cleotide primers used are listed in the Table S1 or described
previously [31].
Cloning and expression of BDCA2 and transmembrane adapters.
Full-length human BDCA2 was cloned from cDNAs generated from
human peripheral blood pDCs by high-ﬁdelity PCR using the
following primers: sense, ATATGGATCCATGGTGCCTGAAGAA-
GAGC and antisense, CTATGAATTCTTATATGT-AGATCTTCTT-
CATC. The BDCA2 cDNA was then cloned into the Bam HI and Eco
RI sites of a lentiviral vector FG-30 [77]. Full-length cDNA encoding
human FceRIc, DAP12, and DAP10, as described previously [31], were
subcloned into FG-30. An FceRIc mutant with Y-to-F substitution in
the ITAM was prepared by PCR and cloned into the FG-30 lentiviral
vector for gene transduction.
NFAT-GFP reporter cell assays. Both BDCA2 and FceRIc, or each
cDNA individually, were transduced into mouse 2B4 T hybridoma
cells stably expressing an NFAT-GFP reporter construct [32]. Trans-
fected cells were cultured at 10
6 cells/ml in the presence of 10 lg/ml of
plate-bound anti-BDCA2 mAb AC144 (Miltenyi Biotec; http://www.
miltenyibiotec.com) or puriﬁed IgG1 isotype-matched control mAb
(eBioscience; http://www.ebioscience.com) for 20 h and then analyzed
for GFP expression by ﬂow cytometry.
Cell surface biotinylation and protein immunoprecipitation. 2 3
10
7 cells that were pre-washed with phosphate-buffered saline (PBS)
were incubated with 2 mM EZ-Link Sulfo-NHS-LC-Biotin (Pierce
Biotechnology; http://www.piercenet.com) according to manufac-
turer’s protocol. Cells were then washed 3 time with 100 mM glycine
in 13 PBS, and lysed in Brij-NP-40 lysis buffer (0.875% Brij 97,
0.125% Nonidet P-40, 10 mM Tris base, pH 8.0, 150 mM NaCl plus
protease inhibitors). Then the lysates were cleared by a spin at
10,000g for 10 min. The lysates were incubated with either control
mouse IgG1 or anti-BDCA2 mAb conjugated to Protein G-Sepharose
(Pierce Biotechnology) at 4 8C overnight. The sepharose beads were
washed extensively with the lysis buffer before elution of the antigen
with SDS sample buffer. Western blots were performed with rabbit
anti- FceRIc antibody (gift from Dr. M-H Jouvin, BIDMC, Boston) and
HRP-conjugated goat anti-rabbit IgG or HRP-labeled neutravidin
(Pierce Biotechnology).
Western blot analysis of protein tyrosine phosphorylation and
expression. 5 3 10
5 cells transfected with BDCA2 and FceRIc were
incubated with control mouse IgG1 (eBioscience) or anti-BDCA2
mAb (Miltenyi Biotec), and then crosslinked with F(ab’)2 goat anti-
mouse IgG (Jackson ImmunoResearch Lab; http://www.
jacksonimmuno.com). BCR crosslinking was performed by adding
15 lg/ml F(ab’)2 goat anti-human Ig (Southern Biotech). 5310
5 pDCs
isolated using a BDCA-4 cell isolation kit (Miltenyi Biotec) were
incubated with control mouse IgG1, anti-BDCA2, or anti-BDCA-4
mAb (Miltenyi Biotec). Western blot was performed with anti-
phospho Src family Ab, anti-phospho Syk Ab, anti-phospho Erk1/2,
anti-non-phospho Src family Ab, anti-Syk Ab (Cell Signaling
Technology; http://www.cellsignal.com), anti-phospho BLNK, anti-
phospho Vav1 (Abcam; http://www.abcam.com), anti-phospho PLCc2
(BD Biosciences; http://www.bdbiosciences.com), and anti-b-actin
mAb (Sigma; http://www.sigmaaldrich.com).
Calcium inﬂux assay. 10
6 transfected cells or pDCs, pre-loaded
with Fluo4- and Fura Red-AM (Invitrogen), were crosslinked as
described above and analyzed on a FACSAria (BD Biosciences) and
data were evaluated by using FlowJo software (TreeStar; http://www.
treestar.com). As indicated, cells were pre-incubated for 30 min with
25 lM PP2, 25 lM PP3, or 5 lM Syk inhibitor (EMD Biosciences;
http://www.emdbiosciences.com) prior to crosslinking.
Namalwa transfectants. Namalwa cells were transduced sequen-
tially by lentiviral vectors expressing human IRF7, BDCA2, and
FceRIc. Full-length human IRF7 was cloned from cDNAs generated
from puriﬁed human peripheral pDCs using a high-ﬁdelity Taq
polymerase (Invitrogen) with primers; sense, ACCTCTA-
GAATGGCCTTGGCTCCTGAGAGG, and antisense, ATTCTCGAGC-
TAGGCGGGCTGCTCCAGCTCC. The transduced Namalwa cells
were stimulated with CpG ODN 2006 and then cultured in the
presence of 10 lg/ml of plate-bound anti-BDCA2 mAb AC144, F(ab’)2
goat anti-human Ig, or puriﬁed control IgG1 for 20 h. Supernatants
were analyzed for cytokine secretion by ELISA using a human IFNa kit
(Bender MedSystems; http://www.bendermedsystems.com) and IL-10
kit (R&D Systems; http://www.rndsystems.com).
BDCA2 crosslinking on pDCs in culture. 5 3 10
4 pDCs isolated by
enrichment with anti-BDCA-4–coated microbeads and subsequent
ﬂow cytometry (CD4
þCD11c
 CD3
 CD14
 CD16
 CD19
 CD56
 ) were
incubated with 5 lg/ml anti-BDCA2 or control mAb in 100 ll culture
medium for 30 min prior to stimulation with 1 lM CpG 2216 or 0.05
lg/ml of R848. Cells and supernatants were harvested 18 h later for
real-time quantitative PCR analysis and enzyme-linked immunosorb-
ent assay (ELISA) using a human IFNa kit (Bender MedSystems), IFNa
kit (PBL Biomedical Laboratories; http://www.interferonsource.com),
IL-6 kit, TNFa kit, CXCL10 kit, CCL3 kit, and CCL4 kit (R&D
Systems). For kinetic studies, pDCs were stimulated with 1 lM CpG
2216 and co-cultured with anti-BDCA2 or control mAbs at time 0. At
different time points, supernatants were harvested for quantitation of
cytokines or IFN by ELISA. Alternatively, CpG was added ﬁrst to pDC
cultures, and then anti-BDCA2 or control mAbs were added at
different times thereafter. Eighteen h after addition of CpG,
supernatants were harvested for quantitation of cytokines or IFN by
ELISA.
Supporting Information
Figure S1. Expression Levels of BDCA2 in the Presence and Absence
of FceRIc on Transfected T Cells (Mouse 2B4 T Hybridoma and
Human Jurkat Cell Lines) and Transfected B Cells (Human HPB-Null
Cell Line)
Found at doi:10.1371/journal.pbio.0050248.sg001 (79 KB PPT).
Figure S2. Relative Transcription of Intracellular Molecules Involved
in Antigen Receptor Signaling in Four Lymphoid Cell Types Based on
Microarray Gene Expression Analysis
Found at doi:10.1371/journal.pbio.0050248.sg002 (57 KB PPT).
Figure S3. Blocking of Tyrosine Phosphorylation of BCR-Like
Intracellular Signaling Components Induced by BDCA2 Crosslinking
by Inhibitors of Src PTK or Syk in Freshly Isolated pDCs
Found at doi:10.1371/journal.pbio.0050248.sg003 (276 KB PDF).
Figure S4. Crosslinking of BDCA2 Inhibits TLR-Induced IFNb but
Not Chemokine Production
Puriﬁed pDCs were stimulated by CpG following anti-BDCA2 or
control Ab crosslinking. The amounts of secreted IFNb, CXCL10/IP-
10, CCL3/MIP-1a and CCL4/MIP-1b from a representative donor (n  
3) are shown.
Found at doi:10.1371/journal.pbio.0050248.sg004 (49 KB PPT).
Figure S5. Puriﬁed pDCs Were Co-Stimulated by CpG and mAbs
(Anti-BDCA2 or Control IgG) for 4 or 8 Hours
The relative amounts of the secreted IFNa from four donors are
shown. The median expression is marked by a horizontal bar. The
numbers on top of the symbols indicate the average amounts of IFNa
(pg/ml) present in the culture supernatant.
Found at doi:10.1371/journal.pbio.0050248.sg005 (44 KB PPT).
Figure S6. Relative Transcription of Intracellular Molecules Involved
in NF-jB Activation in Peripheral Immune Cells Based on Microarray
Gene Expression Analysis
Found at doi:10.1371/journal.pbio.0050248.sg006 (49 KB PPT).
Table S1. Oligonucleotide Primers Used
Found at doi:10.1371/journal.pbio.0050248.st001 (26 KB DOC).
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